﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Infectious Diseases</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Infectious Diseases"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364430v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364449v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.01.26363073v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.25.26363765v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364316v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.24.26363601v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26364156v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.24.26362359v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.22.26363331v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363796v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26363670v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.26.26364094v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.28.26364044v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.27.26364088v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363554v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.25.26364053v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.25.26363952v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.27.26364104v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.25.26363929v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.24.26363964v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.24.26363927v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.21.26363521v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.22.26363724v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.24.26363858v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363816v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.22.26363691v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363603v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.22.26363646v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.22.26363659v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.22.26363680v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364430v1?rss=1">
<title>
<![CDATA[
Subclinical hepatorenal biomarker alterations and urogenital indicators in Schistosoma haematobium-infected School-Aged Children in Sene West District, Ghana 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364430v1?rss=1
</link>
<description><![CDATA[
Urogenital schistosomiasis, caused by Schistosoma haematobium, remains a major public health challenge among school-aged children in rural Ghana. Although urogenital indicators are well-established, systemic hepatic biomarker alterations in post-mass drug administration pediatric settings remain poorly characterized. This cross-sectional study evaluated point-of-care urinalysis profiles alongside a panel of serum hepatic and renal biomarkers in 174 children (aged 3 to 16 years) from the Sene West District, Ghana. Active infection (urine microscopy egg detection) was identified in 84 participants (48.3%, median egg count = 4.50 eggs/10 mL, IQR: 1.00 - 9.25). Active infection was strongly associated with microhematuria (57.1% vs. 11.1%, p < 0.001), proteinuria (42.9% vs. 22.2%, p = 0.004), and leukocyturia (27.4% vs. 4.4%, p < 0.001). Children with active infection also demonstrated a higher frequency of composite categorical hepatic biomarker alterations (60.7% vs. 37.8%, p = 0.002), whereas categorical renal alterations showed no significant difference (p = 0.332). Controlling for age and sex, multivariable logistic regression confirmed active infection as a significant independent predictor of composite hepatic biomarker alterations (aOR = 2.54, 95% CI: 1.37 - 4.69, p = 0.003), but not renal alterations (aOR = 1.40, p = 0.359). Continuous medians for individual serum biomarkers showed no significant differences between groups. Combining composite hepatic biomarker thresholds with routine dipstick screening improves the detection of subclinical morbidity in pediatric field settings.
]]></description>
<dc:creator><![CDATA[ Ofori, D. K., Acheampong, A., Kudzordzi, P.-C., Nyarko, P., Nseide, C. W., Boateng, E. A., Tanko, Y. S., Caffrey, C. R., Otabil, K. B. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364430</dc:identifier>
<dc:title><![CDATA[Subclinical hepatorenal biomarker alterations and urogenital indicators in Schistosoma haematobium-infected School-Aged Children in Sene West District, Ghana]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364449v1?rss=1">
<title>
<![CDATA[
Real-time situational assessment of respiratory virus epidemics in Australia over winter 2025 and an out-of-season influenza A H3N2 epidemic 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364449v1?rss=1
</link>
<description><![CDATA[
Introduction: In temperate regions, influenza and respiratory syncytial virus (RSV) typically exhibit seasonal epidemics during the winter months, often concurrently with SARS-CoV-2 epidemics. Monitoring past and real-time trends in infection dynamics is important for informing public health situational awareness, including identifying and characterising unusual epidemic activity. However, data used to monitor these trends can exhibit substantial noise including strong day-of-the-week variation in reporting. In addition, case data for influenza can obscure distinct trends in influenza subtypes if not combined with virological data. Aim: By quantifying trends in respiratory virus activity using statistical methods, the Australia-Aotearoa Consortium for Epidemic Forecasting and Analytics (ACEFA) aims to provide government partners with comprehensive epidemic intelligence. Methods: Analyses were performed on daily case time series data for SARS-CoV-2, RSV and influenza across Australia's eight jurisdictions. Past and real-time trends were inferred for each pathogen and each influenza subtype using Bayesian p-spline models. Results: The 2025 Winter Situational Assessment Program provided weekly reports throughout the winter season and during the out-of-season influenza A H3N2 epidemic, driven by the emergence of the novel influenza subclade ('subclade K'). Despite limited subtyping data, our analysis provided an early signal of increasing influenza A H3N2 during a period in which overall influenza cases were decreasing; increases in influenza A H3N2 activity were first detected in July, and by mid-August, increasing H3N2 activity was estimated across all jurisdictions. Discussion: Our analysis highlights the benefits of incorporating statistical methods into real-time epidemic situational assessment and in consolidating reporting across jurisdictions.
]]></description>
<dc:creator><![CDATA[ Eales, O., Young, A. R., Senior, K. L., Tobin, R., Amin, J., Archer, B. N., Armstrong, P., Ellis, S., Robinson, E. J., Strachan, J., Shrestha, A. C., Veitch, M., Wood, J., McCaw, J. M., Shearer, F. M. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364449</dc:identifier>
<dc:title><![CDATA[Real-time situational assessment of respiratory virus epidemics in Australia over winter 2025 and an out-of-season influenza A H3N2 epidemic]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26363073v1?rss=1">
<title>
<![CDATA[
Parametric Models for Predicting Gram-negative Antibiotic Susceptibility Phenotype: A Brief Report 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26363073v1?rss=1
</link>
<description><![CDATA[
Predicted probabilities of antibiotic susceptibility to known or suspected pathogens can be used to support antibiotic selection. Patient demographic, clinical, and prior microbiologic history can be used to generate location-specific prediction models. For three Canadian tertiary care institutions we fit and evaluated models for predicting Gram-negative antibiotic susceptibilities to common antimicrobial agents based on previously established model structures. A web-based application was developed to permit visualization of antibiotic susceptibility predictions and support antibiotic decision-making.
]]></description>
<dc:creator><![CDATA[ Garg, A., Graham, C., Daneman, N., MacFadden, D. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26363073</dc:identifier>
<dc:title><![CDATA[Parametric Models for Predicting Gram-negative Antibiotic Susceptibility Phenotype: A Brief Report]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26363765v1?rss=1">
<title>
<![CDATA[
VSV-EBOV vaccination induces cross-reactive T-cell responses against Bundibugyo virus in humans 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26363765v1?rss=1
</link>
<description><![CDATA[
Bundibugyo ebolavirus (BDBV) is causing an ongoing outbreak in the Democratic Republic of Congo (DRC) with no licensed vaccine available. Recent reports have shown the presence of BDBV-cross-reactive antibody responses in humans vaccinated against the related Ebola virus (EBOV). Here, we used an IFN-{gamma} ELISpot assay to assess T cell responses against the EBOV, BDBV and SUDV glycoproteins in clinical trial participants vaccinated with the licensed VSV-EBOV vaccine. We could show that BDBV-cross-reactive T cell responses are detectable in the majority of individuals and that conserved regions within the glycoprotein are targeted. In the absence of a BDBV-specific vaccine, these data support efficacy trials of the VSV-EBOV vaccine during the current outbreak.
]]></description>
<dc:creator><![CDATA[ Mayer, L., Londt, R., Gruener, E., Ly, M. L., Addo, M. M., Geldmacher, C. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26363765</dc:identifier>
<dc:title><![CDATA[VSV-EBOV vaccination induces cross-reactive T-cell responses against Bundibugyo virus in humans]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364316v1?rss=1">
<title>
<![CDATA[
Correlates of Protection and Response Durability of the RTS,S Vaccine in Four Malaria Challenge Studies 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364316v1?rss=1
</link>
<description><![CDATA[
RTS,S/AS01 (RTS,S) is one of two WHO-recommended malaria vaccines for children in moderate-to-high transmission settings. Yet, no validated immune correlate of protection (CoP) has been established for this vaccine. We selected 16 biomarkers to further assess as candidate CoPs, based largely on their ability to well-predict post-challenge outcomes in a previous integrative correlates analysis of two phase 2a controlled human malaria infection (CHMI) studies, Malaria-068 and Malaria-071. We evaluated the predictive power of these 16 biomarkers in two additional phase 2a CHMI studies, Malaria-092 and Malaria-102, to confirm these candidate CoPs in new malaria vaccine trials. In MAL092, malaria-naive volunteers were challenged three months after a series of two or three doses of RTS,S/AS01, and in MAL102, a subset were boosted nine months later and re-challenged after three weeks. The 16 biomarkers included Plasmodium falciparum circumsporozoite protein (CSP)-specific IgG antibodies targeting the CSP NANP-repeat region (CSP IgG ELISA), NANP repeat-specific antibody binding to human Fc gamma receptors (FcgRs), CSP-specific antibody Fc effector functions, total NANP6-specific serum Ig measured by biolayer interferometry (BLI), and NANP6-specific IgG1 antibodies measured by binding antibody multiplex assay. Immunogenicity analyses confirmed that the vaccine regimens elicited robust immune responses, including multiple biomarkers not previously reported on, in both trials. In MAL092, participants clustered into two distinct immunogenicity profiles that overlapped with malaria protection status. In univariate logistic regression analyses, most biomarkers were significantly associated with protection when measured on the day of challenge in both trials. Notably, the same three biomarkers ranked as top correlates in both trials (FCGR2AH NANP6, FCGR2AR NANP6, and FCGR2B NANP6; all adjusted p-values <0.001), with similar effect sizes across studies. Despite these strong associations, no biomarker demonstrated significantly better individual-level predictive performance than CSP IgG ELISA. In MAL092, CSP IgG ELISA achieved an area under the curve (AUC) [95% confidence interval (CI)] of 0.74 (0.63, 0.84), compared with AUCs of 0.76 - 0.78 for the top five biomarkers, all of which reflected NANP6-specific Fc{gamma}R binding (all adjusted p-values > 0.37 versus CSP IgG ELISA). Predictive models trained on data from two prior CHMI studies and applied to MAL092 and MAL102 identified a model based on FCGR2B NANP6 (validation AUC = 0.77 in MAL092; 0.80 in MAL102) as the best-performing univariate model for both studies. The best-performing multivariate predictive model for MAL092 was based on BLI NANP6 Dissociation AUC and ADCP NANP6 (validation AUC = 0.76), and in MAL102, it was based on CSP IgG ELISA, BLI NANP6 Dissociation AUC, and ADCP NANP6 (validation AUC = 0.82). The next approximately 10 highest-ranked models, however, had comparable performance with overlapping 95% CIs, and none were clearly superior to CSP IgG ELISA (validation AUCs 0.74 and 0.71 in MAL092 and MAL102, respectively). Collectively, these findings suggest that the majority of the previously identified candidate CoPs also hold up well in two additional malaria vaccine CHMI trials and underscore the continued utility of the CSP IgG ELISA readout as a robust marker of protection. Further studies are needed to determine whether these candidate CoPs hold in malaria-endemic field settings. Identifying validated CoPs that predict malaria vaccine efficacy would promote the development and approval of more effective and durable next-generation vaccines. These advances could also inform vaccine strategies for other infectious diseases.
]]></description>
<dc:creator><![CDATA[ Kim, S.-Y., Linnekin, T., Carpp, L. N., Lee, C. K., Ockenhouse, C. F., Mercer, L. D., Gregory, S., Linde, C., Suscovich, T., Shneer, T., Seaton, K. E., Dennison, S. M., Spreng, R. L., Mudrak, S. V., Fontana, L., Holman, D., Shotorbani, S., Das, J., Moon, J. E., Kisalu, N., Moise, L., Alter, G., Tomaras, G., Hyrien, O. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364316</dc:identifier>
<dc:title><![CDATA[Correlates of Protection and Response Durability of the RTS,S Vaccine in Four Malaria Challenge Studies]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.24.26363601v1?rss=1">
<title>
<![CDATA[
Persistent Borrelia burgdorferi protein antigen in CD16⁺ monocytes is associated with monocyte-skewed immune dysregulation in post-treatment Lyme disease syndrome (PTLDS) 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.24.26363601v1?rss=1
</link>
<description><![CDATA[
Post-treatment Lyme disease syndrome (PTLDS) is characterized by persistent symptoms after antibiotic therapy for Borrelia burgdorferi infection. The mechanisms underlying these symptoms remain incompletely understood and have been attributed to ongoing low-level infection, autoimmunity, or immune dysregulation driven by residual bacterial antigens. We investigated whether Borrelia burgdorferi protein antigen persists in long-lived monocyte subsets in PTLDS patients and is associated with broader immune dysregulation. CD14CD16 monocytes from 10 patients with PTLDS were analyzed by mass spectrometry; plasma from all 10 was profiled on a 14-plex cytokine panel against 50 healthy donors; PBMCs from 6 patients (3 antigen-positive and 3 antigen-negative) underwent RT-qPCR and bulk RNA-seq with immune-compartment profiling. FlaB and OspC were detected in CD14CD16 monocytes months to years after treatment, whereas Borrelia burgdorferi transcript was not detected. Plasma IFN-{gamma} exceeded the healthy donor median in all 10 participants. Antigen-positive samples showed an antigen-associated inflammatory transcriptional profile, including increased TNFSF14/LIGHT, GSDMD, GBP5, and KCNJ2 expression, together with a compartment-level pattern of monocyte-skewed myeloid reconfiguration, higher neutrophil-related features, and selective T-cell-state changes. These findings link residual Borrelia burgdorferi protein in CD14CD16 monocytes to monocyte-skewed immune remodeling in PTLDS, paralleling observations in long COVID and supporting a model in which post-infectious syndromes are sustained by antigen-fueled immune remodeling rather than ongoing infection.
]]></description>
<dc:creator><![CDATA[ Patterson, B. K., Francisco, E. B., Castano, N., Medetgul-Ernar, K., Beaty, C., Beaty, K., Felder, P. A., Yogendra, R. ]]></dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.24.26363601</dc:identifier>
<dc:title><![CDATA[Persistent Borrelia burgdorferi protein antigen in CD16⁺ monocytes is associated with monocyte-skewed immune dysregulation in post-treatment Lyme disease syndrome (PTLDS)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364156v1?rss=1">
<title>
<![CDATA[
Incidence and factors associated with infections in kidney transplant recipients at the tertiary hospital, Thailand. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364156v1?rss=1
</link>
<description><![CDATA[
Background/Aims: In medical practice, the rising prevalence of infections in kidney transplant recipients (KTRs) is a notable concern. However, understanding the incidence and risk factors associated with infections in KTRs remains limited. This study aims to assess the incidence and factors associated infection among KTRs. Additionally, we also investigate the median time of each infection among KTRs. Methods: A retrospective cohort study was conducted from 1 January 2018- 31 December 2022 at Thailand's tertiary hospital. We performed univariable and multivariable logistic regression analyses to identify potential risk factors related infection and investigated for the incidence and median time of each infection among KTRs. Results: A total of 179 participants were included in this study. Our findings reveal the kidney from living donor was protective factor for infection among KTRs (aOR 0.063, 95% CI 0.005-0.792; p = 0.032). Urinary tract infections (UTIs)showed as the predominant pathogenic manifestation among KTRs (43%). The median time of UTIs, cytomegalovirus (CMV) infection and pneumocystis pneumonia (PCP) were 16, 57 and 94.5 days, respectively. Conclusions: Our study establishes that receiving a kidney from a living donor is a protective factor against post-kidney transplant infections. Particularly urinary tract infections were most common of infection. Monitoring urinary tract infections post-transplantation is recommended. Moreover, awareness of UTI, CMV infection and PCP should be concerned during 2-3 months after transplantation. However, due to a small sample size; we recommend to increase the number of particular participants in further investigations.
]]></description>
<dc:creator><![CDATA[ Phacharoen, S., Prawang, A., Kanchanasurakit, S., Phonphok, K., Duangrithi, D., Petchcharee, P., Sangsanit, W., Jintasataporn, R. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364156</dc:identifier>
<dc:title><![CDATA[Incidence and factors associated with infections in kidney transplant recipients at the tertiary hospital, Thailand.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.24.26362359v1?rss=1">
<title>
<![CDATA[
Genomic epidemiology reveals post-vaccine re-emergence of vaccine-associated G1P rotavirus lineages with variable disease severity 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.24.26362359v1?rss=1
</link>
<description><![CDATA[
Group A rotavirus G1P[8] strains, which are targeted by the Rotarix vaccine, have persisted in several countries following the introduction of the Rotarix vaccine. However, the evolutionary origins of the persisting strains remain unclear. Here, we leveraged over two decades of rotavirus surveillance data from Malawi to understand the genomic epidemiology of G1P[8] strains in a high-disease-burden sub-Saharan African setting. We observed a reversion of G1P[8] strains to the conventional Wa-like genotype constellation identified pre-vaccination, following transient circulation of DS-1-like G1P[8] strains. Most G1P[8] lineages that re-emerged post-vaccination circulated before vaccine introduction. Furthermore, new strains emerged post-vaccination through re-assortment of pre-existing viruses. The predominant post-vaccination lineage (MW-VP7-L2) contained an N147D substitution at an antigenically important site of the VP7 glycoprotein and showed evidence of episodic diversifying selection. Children infected with the MW-VP7-L2 lineage had a higher severity score of gastroenteritis than infections with other co-circulating lineages. These findings highlight the importance of long-term genomic surveillance to understand rotavirus transmission, evolution, and disease severity, and to guide public health interventions.
]]></description>
<dc:creator><![CDATA[ Mhango, C., Chinyama, E., Banda, A., Wachepa, R., Gauti, L., Matambo, E., Kawonga, F., Ndovie, W., Chaima, D., Zuza, A., Kalizang'oma, A., Mhango, M., Cunliffe, N. A., Tshiswaka, N. J., Mogotsi, M. T., Ogunbayo, A. E., Dennis, F. E., Nyaga, M. M., Kumwenda, B., Donato, C. M., Kamng'ona, A. W., Chaguza, C., Jere, K. C. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.24.26362359</dc:identifier>
<dc:title><![CDATA[Genomic epidemiology reveals post-vaccine re-emergence of vaccine-associated G1P rotavirus lineages with variable disease severity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.22.26363331v1?rss=1">
<title>
<![CDATA[
Worsening pre-existing health conditions in U.S. adults with Long COVID 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.22.26363331v1?rss=1
</link>
<description><![CDATA[
PurposeLong COVID literature often describes new-onset symptoms or conditions following SARS-CoV-2 infection; however, Long COVID also encompasses the exacerbation of pre-existing conditions. We describe health conditions reportedly worsened by COVID-19 illness and associated concerns in U.S. adults.

MethodsWe collected longitudinal data from adults 18 years and older participating in the Track Post COVID-19 Conditions, an active Long COVID cohort surveillance project. Respondents completed surveys 3-, 6-, and 12- months after COVID-19 illness, beginning in July 2023. In each survey, respondents were asked whether they had any health conditions or concerns that were made worse by COVID-19. Those with an affirmative response were asked to specify the worsening condition(s) via free text. Some respondents used this free text to describe challenges or experiences related to their worsening conditions. This report categorizes and quantifies reported conditions and concerns by body system categories and qualitatively describes associated challenges and experiences using direct quotes from respondents free text responses.

ResultsAmong 2,227 adults, 263 (11.8%) respondents reported at least one worsening condition or concern following COVID-19 illness. Of these, nearly 32% reported a worsening respiratory condition or concern. Adults with worsening pre-existing conditions reported challenges accessing adequate care, completing daily activities, and managing their symptoms following COVID-19.

DiscussionWhile Long COVID literature often focuses on the development of new-onset long-term symptoms, more than 1 in 10 adults reported worsening of a pre-existing condition following COVID-19. Reported challenges with accessing care and daily activities highlight potential need for accommodations or support for adults with Long COVID.
]]></description>
<dc:creator><![CDATA[ Edwards, D., Rollins, A., Ford, N., Pratt, C., Bloodworth, R., Pogreba-Brown, K., Jones, R., Sharma, V., Reina Ortiz, M., Saydah, S. ]]></dc:creator>
<dc:date>2026-09-26</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.26363331</dc:identifier>
<dc:title><![CDATA[Worsening pre-existing health conditions in U.S. adults with Long COVID]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363796v1?rss=1">
<title>
<![CDATA[
Coming Into Resistance: Clinically Important Antibiotic Resistance Genes in NICU vs. Healthy Infants 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363796v1?rss=1
</link>
<description><![CDATA[
ImportanceAntibiotic-resistant infections in neonates often arise from the infants own colonizing bacteria harboring antibiotic resistance genes (ARG). This study evaluates ARG that impact antibiotic selection and drive resistance-related mortality, termed clinically important antibiotic resistance genes (CI-ARG).

ObjectiveTo determine differences in gut CI-ARG abundance in children from birth through 3 years old, stratified by neonatal intensive care unit (NICU) admission and antibiotic (abx) exposure in the first two months

DesignCohort study (sequencing, analysis completed 2025-2026) using shotgun metagenomic sequencing of stool samples from infants in two studies: "Neonatal Intestinal Microbiome" (+NICU groups, 2015-2022), "The First 1000 Days of Life and Beyond" (-NICU groups, 2018-2021). Infants grouped into four cohorts: +NICU/+abx, +NICU/-abx, -NICU/-abx, and -NICU/+abx. Prespecified CI-ARG abundance compared longitudinally among groups.

SettingNICU, well-baby nursery, Inova Fairfax Hospital, Virginia

Participants+NICU criteria: admission to the NICU, anticipated length of stay (LOS) of at least five days, maternal age [&ge;]18 years. -NICU: parents with good general health and age [&ge;]18 years enrolled prior to infant birth. Stool samples: adequate stool processing volume, at least one stool sample from before one month and after one year of age, 7-day minimum between serial samples.

ExposuresNICU versus well-baby nursery; antibiotics versus none in first two months of corrected age

Main Outcomes and MeasuresPredefined primary outcome-longitudinal CI-ARG abundance by group, compared using linear mixed effects models with adjustment for multiple comparisons (Benjamini-Hochberg procedure). Predefined secondary outcomes-differences in overall microbiota and resistome composition.

Results1000 serial stool samples, 179 infants (birth-39 months). Longitudinal abundance significantly differed among cohorts for 11 CI-ARG (p<0.05); often higher in the +NICU groups in early life, with or without antibiotic exposure. Abundance of ARG conferring resistance to aminoglycosides, macrolides, and fluoroquinolones later decreased below -NICU levels. mecA, which often drives methicillin resistance in Staphylococcus, was detected only in +NICU infants during premature period.

ConclusionsThis longitudinal study demonstrates significant longitudinal CI-ARG differences in children grouped by early-life NICU status and/or antibiotic exposure. Future studies should explore the mechanisms driving these CI-ARG changes and evaluate their impact on infection risk and community spread.

Key PointsO_ST_ABSQuestionC_ST_ABSHow do clinically important antibiotic resistance genes (CI-ARG) differ longitudinally among infants up to 3 years old based on NICU admission and antibiotic exposure in the first two months of life?

FindingsIn this cohort study of 179 infants through 39 months of age, longitudinal abundance was significantly different for 11 prespecified CI-ARG, often higher in the NICU groups in early life, with or without antibiotic exposure.

MeaningChildren with a history of NICU hospitalization, whether due to the NICU environment itself, prematurity, or other factors, may have increased CI-ARG burden early in life, irrespective of direct antibiotic exposure.
]]></description>
<dc:creator><![CDATA[ Strength, R. E., Angelova, A., Robbins, E., Levy, S., McCauley, K. E., Lloyd, K. M., Margolis, E. B., Burns, A. S., Mistry, S., Subramanian, P., Dassner, A., Zerbe, C., Band, V. I., Namasivayam, S., Chen, Q., Esadah, E., Rees, K., Bacorn, M., Prasad, R., LaPoint, P., Romero-Soto, H. N., Dekker, J. P., Sears, C. L., Shapiro, C., Hamdy, R. F., Campos, J. M., Hourigan, S. K. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363796</dc:identifier>
<dc:title><![CDATA[Coming Into Resistance: Clinically Important Antibiotic Resistance Genes in NICU vs. Healthy Infants]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26363670v1?rss=1">
<title>
<![CDATA[
A mechanistic framework for interpreting blood-stage malaria vaccine efficacy 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26363670v1?rss=1
</link>
<description><![CDATA[
Blood-stage vaccines (BSVs) against malaria offer a promising avenue for reducing parasite burden and transmission, yet their efficacy is challenging to interpret across different trial phases. In this study we develop a simple mechanistic within-host mathematical model of Plasmodium falciparum asexual parasitaemia. We fit this model to individual-level data from the phase I/IIa RH5.1 trial and estimate the relationship between vaccine efficacy and RH5 antibody titres, enabling the quantitative prediction of vaccine-impact on public health outcomes. We show that small reductions in erythrocyte invasion rate can lead to substantial decreases in probability of exceeding parasitaemia thresholds and transmission potential. Our framework provides a flexible, biologically motivated method for interpreting early-phase trial data and can inform future trial design, vaccine evaluation and integration into broader malaria control strategies.
]]></description>
<dc:creator><![CDATA[ Wood, J. R., Challenger, J., Churcher, T., Okell, L., Ghani, A. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26363670</dc:identifier>
<dc:title><![CDATA[A mechanistic framework for interpreting blood-stage malaria vaccine efficacy]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.26.26364094v1?rss=1">
<title>
<![CDATA[
Integrated CRISPR-based detection of HIV, tuberculosis, malaria, and resistance-associated variants 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.26.26364094v1?rss=1
</link>
<description><![CDATA[
HIV, tuberculosis (TB) and malaria are major infectious diseases that frequently co-circulate in high-burden settings, yet their diagnostic pathways remain largely disease-specific, complicating detection of coinfection and integration of antimicrobial-resistance testing. Here we developed HTM CARMEN, a highly multiplexed CRISPR-Cas13a molecular-testing framework that integrates detection of HIV-1, HIV-2, four Plasmodium species and Mycobacterium tuberculosis (Mtb) with detection of isoniazid-resistance-associated inhA and katG variants. We find that HTM CARMEN retained target selectivity and single-nucleotide discrimination across in vitro experiments and clinically relevant sample matrices, including whole blood, serum, sputum and dried blood spots. Across 20 contrived samples for each condition, the HTM panel supported detection of low-abundance targets across multiple matrices and frequently detected greater number of low-input samples as positive than qPCR under the conditions tested. In contrived P. falciparum/HIV-1 and Mtb/HIV-1 coinfections, both pathogens were simultaneously detected across a range of relative target concentrations. Using confirmed-positive clinical samples, HTM CARMEN achieved positive percent agreement of 95% for malaria (19/20), 95% for HIV-1 (19/20) and 100% for Mtb (30/30), with 100% negative percent agreement for each target in the confirmed-negative samples. Both HIV-1 and Mtb were additionally detected in all nine confirmed-positive HIV-TB coinfection specimens. These findings establish the feasibility of integrating pathogen detection, species differentiation, resistance-associated variant interrogation and coinfection detection within a programmable molecular-testing platform, providing a framework for high-throughput integrated testing in co-endemic settings.
]]></description>
<dc:creator><![CDATA[ Jain, A. S., Si, A., Yap, J., Schwartz, L. A., Susilo, C., Balamurugan, A., Neal, A., Le Roch, K. G., Yang, O., Garner, O., Kamariza, M. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.26.26364094</dc:identifier>
<dc:title><![CDATA[Integrated CRISPR-based detection of HIV, tuberculosis, malaria, and resistance-associated variants]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364044v1?rss=1">
<title>
<![CDATA[
Antiviral Antibody Fc Dysfunction Is Linked to Increased IgG1 Fucosylation in Long COVID 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364044v1?rss=1
</link>
<description><![CDATA[
BackgroundPersistent SARS-CoV-2 antigen is a leading hypothesis for post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. Impaired Fc-mediated antiviral antibody function could contribute to inefficient clearance of infected cells and viral antigen despite preserved antibody levels. Therefore, we tested whether PASC is associated with altered Fc{gamma} receptor-mediated antibody function and differences in IgG1 Fc fucosylation, a major regulator of Fc effector function.

MethodsSerum samples from RECOVER-Adult participants with prior SARS-CoV-2 infection (99 PASC, 139 non-PASC) were analyzed for anti-SARS-CoV-2 spike receptor-binding domain (RBD) IgG and subclasses, Fc{gamma}RIIIa- and Fc{gamma}RIIa-mediated reporter activity as surrogate measures of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), anti-RBD IgG1 Fc glycosylation, and circulating fucose-modifying enzymes.

ResultsDespite higher anti-RBD IgG and IgG1 abundance, PASC sera showed lower ADCC- and ADCP-associated Fc{gamma}R reporter activity, including after normalization for antibody abundance. Anti-RBD IgG1 showed greater fucosylation in PASC samples (30 PASC, 34 non-PASC). Serum FUCA2 was lower in PASC samples (24 PASC, 34 non-PASC), whereas FUCA1 and soluble CD16a levels did not differ between the two groups.

ConclusionPASC is associated with impaired antiviral IgG Fc function, increased IgG1 Fc fucosylation, and reduced circulating FUCA2, identifying a glycoimmune axis that may contribute to impaired Fc-dependent antigen clearance and represents a potentially targetable pathway in Long COVID.
]]></description>
<dc:creator><![CDATA[ Ukey, R., Michailidis, I. E., Greenberg, P., Andrews, T., Jung, S. Y., Zheng, H., Honnen, W., Pinter, A., Kleinman, L. C., Bruiners, N., gennaro, m. l. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364044</dc:identifier>
<dc:title><![CDATA[Antiviral Antibody Fc Dysfunction Is Linked to Increased IgG1 Fucosylation in Long COVID]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.27.26364088v1?rss=1">
<title>
<![CDATA[
Amplicon-based targeted next generation sequencing (tNGS) for Mycobacterium tuberculosis - unpacking the 'black box' 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.27.26364088v1?rss=1
</link>
<description><![CDATA[
The WHO recently endorsed two commercial culture-free targeted next-generation sequencing (tNGS) assays for detecting drug resistant Mycobacterium tuberculosis. These proprietary tNGS platforms present a  black box. We developed an in-house tNGS assay using Oxford Nanopore Technology sequencing to detect an expanded range of resistance mutations directly from clinical specimens. The assay targeted 44 genomic loci; hsp65 for Mycobacterium tuberculosis complex (MTBC) identification; 12 loci for MTBC lineage classification; and 31 drug resistance loci predicted resistance to 16 anti-TB drugs. In total, 98 amplicons were distributed across three PCR pools. Analytical sensitivity was assessed using M. tuberculosis H37Rv, and proof-of-concept performance was evaluated in 63 archived clinical specimen extracts and one  real-life sputum specimen in comparison with Illumina whole genome sequencing (WGS). All amplicons were successfully amplified and sequenced from M. tuberculosis H37Rv genomic DNA. At [&ge;]100 genome copies/L, 71.4% of amplicons met [&ge;]20( mean depth across six replicates, including all loci for rifampicin, ethambutol, pyrazinamide, fluoroquinolone and bedaquiline resistance. In 63 clinical specimens, (90% of amplicons achieved a mean depth of (20( in specimens with IS6110 PCR cycle threshold (Ct) values [&le;]24. With Ct value [&le;]27 lineage classification was concordant with WGS in 94.7% (18/19) of specimens and drug-susceptibility prediction showed 94.7% (18/19) agreement with both phenotypic and genotypic (WGS) testing. In a single clinical case (Ct 26.5), lineage and resistance-associated mutations were accurately identified directly from sputum. The findings provide new insights into rapid culture-independent tNGS approaches for rapid M. tuberculosis drug resistance detection with lineage assignment.
]]></description>
<dc:creator><![CDATA[ Zhang, X., Sim, E. M., Lam, C., Bustamante, A., Crighton, T., Marais, B. J., Sintchenko, V. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.27.26364088</dc:identifier>
<dc:title><![CDATA[Amplicon-based targeted next generation sequencing (tNGS) for Mycobacterium tuberculosis - unpacking the 'black box']]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363554v1?rss=1">
<title>
<![CDATA[
Genomic Epidemiology and Genetic Relatedness of Antimicrobial-Resistant Morganella morganii in Community and Hospital Settings in Bangladesh 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363554v1?rss=1
</link>
<description><![CDATA[
Morganella morganii is an opportunistic pathogen with intrinsic and acquired antimicrobial resistance, but its genomic epidemiology remains poorly characterized in Bangladesh. We sequenced and compared genomes of 47 stool-derived M. morganii isolates from hospital (n = 29) and community (n = 18) participants in urban Dhaka.

Susceptibility testing showed frequent resistance to imipenem (70{middle dot}2%) and cefuroxime (97{middle dot}9%), while all isolates were resistant to colistin. Resistance to meropenem (6{middle dot}4%) and ertapenem (2{middle dot}1%) was uncommon. Based on acquired non-susceptibility across tested antimicrobial categories, 18/47 (38{middle dot}3%) isolates were multidrug-resistant, including 15/29 (51{middle dot}7%) hospital-derived and 3/18 (16{middle dot}7%) community-derived isolates. Genomic analysis identified 17 {beta}-lactamase alleles including Morganella-associated chromosomal {beta}-lactamases and acquired resistance determinants, with blaOXA-1, blaDHA-21, blaCTX-M-15, and blaTEM-1 predominating. However, no recognized acquired carbapenemase genes were detected. Among 44 non-{beta}-lactam resistance genes, tetB was most frequent.

Phylogenomic and average nucleotide identity analyses classified 31 isolates as M. morganii subsp. morganii and 16 as the subsp. intermedius lineage. Considerable population diversity was observed, with 33 distinct sequence types among the 47 isolates and no clear clustering by hospital or community origin. The subsp. intermedius isolates showed greater genomic heterogeneity than subsp. morganii, with a minimum within-group average nucleotide identity of 94{middle dot}2%. Single nucleotide variant (SNV) analysis identified several closely related isolate groups, including an ST1 pair differing by 10 SNVs and collected three days apart within the same hospital, although direct transmission could not be established.

Virulence-associated gene profiles differed between subspecies, with hemolysin- and toxin-associated genes predominantly detected among subsp. morganii isolates and largely absent from subsp. intermedius. Overall, these findings reveal substantial genomic diversity, a considerable burden of multidrug resistance, and subspecies-associated differences in virulence gene content among M. morganii circulating in Dhaka, while the frequent imipenem-non-susceptible but carbapenemase-negative phenotype highlights the need to investigate alternative carbapenem resistance mechanisms.
]]></description>
<dc:creator><![CDATA[ Rahman, T., Khan, T., Haider, A., Moon, S. B., Samia, N. S. N., Mah-E-Muneer, S., Mamun, G. M. S., Chowdhury, F., Rahman, M., Jubair, M. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363554</dc:identifier>
<dc:title><![CDATA[Genomic Epidemiology and Genetic Relatedness of Antimicrobial-Resistant Morganella morganii in Community and Hospital Settings in Bangladesh]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26364053v1?rss=1">
<title>
<![CDATA[
Spatiotemporal clustering of tuberculosis notifications in Nepal during the COVID-19 pandemic and subsequent recovery: A national space-time scan analysis, 2019-2024 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26364053v1?rss=1
</link>
<description><![CDATA[
The COVID-19 pandemic substantially disrupted tuberculosis (TB) prevention, diagnosis, and treatment services worldwide. Despite increased TB notifications in Nepal during the post-pandemic recovery period, the geographic distribution and temporal clustering of notifications remain poorly understood. This study examined the spatial and temporal patterns of TB notifications across Nepal during the COVID-19 recovery period. We conducted a nationwide retrospective ecological analysis of district-level TB notifications across all 77 districts of Nepal from FY 2019/20 to FY 2023/24. Space-time, purely spatial, and purely temporal scan statistics were performed using a discrete Poisson model in SaTScan. Statistical significance was assessed using Monte Carlo simulation with 999 replications. A total of 172,155 TB cases were notified during the study period. TB notification rates increased by 51%, from 92 to 139 per 100,000 population between FY 2019/20 and FY 2023/24. Four statistically significant high-notification space-time clusters were identified (all p < 0.001). The primary cluster included Kathmandu, Lalitpur, Bhaktapur, Makwanpur, Bara, and Parsa districts during FY 2021/22-FY 2023/24 (RR = 1.60). Additional clusters were identified in western Nepal, the eastern Terai, and Rupandehi district. Purely temporal analysis showed a nationwide increase in notifications during FY 2022/23-FY 2023/24 (RR = 1.26, p = 0.001). TB notifications increased substantially during Nepals post-pandemic recovery period, with marked geographic and temporal heterogeneity. Integrating spatial and temporal surveillance may help identify areas requiring geographically targeted TB control strategies.
]]></description>
<dc:creator><![CDATA[ Bisht, N., Bhatt, R., Rijal, P., Gupta, R. K., Bisht, R., Yadav, H., Singh, S., Kalwar, D. K., Adhikari, C. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26364053</dc:identifier>
<dc:title><![CDATA[Spatiotemporal clustering of tuberculosis notifications in Nepal during the COVID-19 pandemic and subsequent recovery: A national space-time scan analysis, 2019-2024]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26363952v1?rss=1">
<title>
<![CDATA[
Diagnostic information from a negative QuantiFERON-TB Gold Plus result in adults evaluated for tuberculosis in Brazil and South Africa 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26363952v1?rss=1
</link>
<description><![CDATA[
Interferon-gamma release assays detect Mycobacterium tuberculosis infection but cannot distinguish infection from active tuberculosis (TB). We evaluated the diagnostic information provided by QuantiFERON-TB Gold Plus (QFT-Plus) among adults investigated for active TB in Brazil and South Africa. Adults with presumptive TB were prospectively enrolled by convenience sampling. QFT-Plus was the index test, and diagnostic classification required microbiological confirmation of TB or an established alternative diagnosis. QFT-Plus results did not inform diagnostic classification. Accuracy was assessed among participants with determinate results, primarily using likelihood ratios. Of 723 participants tested, 48 (6.6%) had indeterminate results, all due to low mitogen responses. Among 675 participants with determinate results, 147 (21.8%) had confirmed TB. Sensitivity was 68.0% (95% CI, 60.1-75.0), specificity was 59.3% (95% CI, 55.0-63.4), and the negative likelihood ratio was 0.54 (95% CI, 0.42- 0.69). At the observed prevalence, a negative result left a 13.1% probability of active TB. Negative likelihood ratio confidence intervals included 1 in both South African HIV strata. Specificity was higher among participants with HIV in both countries. Adding TB2 to TB1 alone identified 15 additional TB cases and generated 18 additional positive results among participants without active TB. HIV and active TB were independently associated with indeterminate results in exploratory regression. A negative QFT-Plus result provided insufficient information to exclude active TB. Higher negative predictive values among participants with HIV reflected lower disease prevalence and higher specificity rather than greater sensitivity. Negative or indeterminate results should not terminate diagnostic evaluation.

IMPORTANCEBlood tests that detect immune responses to Mycobacterium tuberculosis can yield negative results in people with active tuberculosis. Understanding how much reassurance a negative result provides is therefore important when these tests are encountered during diagnostic investigation. Among symptomatic adults in Brazil and South Africa, a negative QuantiFERON-TB Gold Plus result left a substantial probability of active disease. Differences between populations showed why apparently reassuring negative predictive values can be misleading. The additional antigen tube detected more cases but did not overcome the tests limited ability to exclude disease. Indeterminate results were associated with human immunodeficiency virus infection and active tuberculosis. These findings support laboratory reporting and clinical interpretation that clearly communicate the limitations of negative and indeterminate results and the need for continued investigation when active tuberculosis remains suspected.
]]></description>
<dc:creator><![CDATA[ da Costa, A. G., Trajman, A., Borges-Cabral, M. C., Esmail, A., Carvalho, B. K. S., Loiola, B. P., Souza, A. B., Spener-Gomes, R., Jesus, J. s., Sampaio, V. S., Castro, D. B. d., Dheda, K., Cordeiro-Santos, M. ]]></dc:creator>
<dc:date>2026-09-28</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26363952</dc:identifier>
<dc:title><![CDATA[Diagnostic information from a negative QuantiFERON-TB Gold Plus result in adults evaluated for tuberculosis in Brazil and South Africa]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-28</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.27.26364104v1?rss=1">
<title>
<![CDATA[
Reach and uptake of facility- and home-based hepatitis C self-testing in urban slums in Haridwar, India; A Comparative Implementation Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.27.26364104v1?rss=1
</link>
<description><![CDATA[
Routine facility-based testing for hepatitis C virus (HCV) remains underutilised in India despite national screening policy. WHO has recommended HCV self-testing (HCVST) since 2021 to increase access to testing services. This study evaluated the HCVST by assessing its reach and uptake in urban-slum communities within Haridwar, Uttarakhand, India.

The implementation study (CTRI/2023/07/054590) took place between 12th July 2023 and 31st August 2024. Three Primary Healthcare Centre (PHC) catchment areas were assigned to deliver either (1) facility-based HCVST, (2) home-based HCVST, or (3) standard of care (SoC). Facility-based delivery involved trained users offering kits to patients visiting the PHC (Site 1: Jwalapur 1), whereas home-based delivery (Site 2: Jwalapur 2) involved trained users and ASHAs approaching community households selected via a KISH grid. Primary outcomes were OPD-footfall standardized operational reach; the proportion offered testing out of the PHC catchement areas footfall, and uptake (acceptance among those offered). Secondary analysis explored demographic and behavioural predictors of those that refused to test.

Of 7,091 outpatient department (OPD) footfall, 724 (10.2%) individuals were offered HCVST at intervention sites, of which 465 (64.2%) agreed to self-test. Operational reach was 17.8% (393/2,212; 95% CI: 16.2-19.5%) through the facility-based intervention and 14.4% (331/2,296; 95% CI: 13.0-15.9%) in the home-based intervention.HCVST uptake was higher through the home-based model (71.9%, 238/331, 95% CI: 66.7-76.7%) than in the facility (57.8%, 227/393, 95% CI: 52.7-62.7%). At the SoC site, only 11 individuals received standard of care HCV testing. The study HCV positivity was 1.1% (5/465; 95% CI: 0.35%- 2.49%): with four testing positive at the facility site (4/227), one at the community site (1/238), and none at the SoC site (0/11). Men were more likely to refuse HCVST than women (OR 0.54, 95% CI 0.37-0.78, p=0.001).Participants in the facility-based model had 1.87 times higher odds of refusal compared to those in the home-based delivery model.

There is minimal routine HCV testing in the OPD setting of Urban PHCs despite national screening policy. HCVST improved testing coverage and uptake in urban slums compared to SoC. However, HCV positivity was low overall, suggesting that untargeted screening - whether facility-based or home-based - may identify few infections without additional strategies to reach higher-risk populations.
]]></description>
<dc:creator><![CDATA[ Bhadoria, A. S., Mehndiratta, A., Dunkley, Y., Selv, K., Somvanshi, R., Jamil, M. S., Luhmann, N., Johnson, C., Hatzold, K. ]]></dc:creator>
<dc:date>2026-09-28</dc:date>
<dc:identifier>doi:10.64898/2026.09.27.26364104</dc:identifier>
<dc:title><![CDATA[Reach and uptake of facility- and home-based hepatitis C self-testing in urban slums in Haridwar, India; A Comparative Implementation Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-28</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26363929v1?rss=1">
<title>
<![CDATA[
Detecting measles virus in hospital air during a local outbreak 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26363929v1?rss=1
</link>
<description><![CDATA[
In 2024, Chicago experienced a measles virus outbreak. Air samples collected as part of routine respiratory virus surveillance from three hospitals that received measles patients were retrospectively analyzed. Measles virus was detected in air samples from one emergency department across five weeks when measles patients were present and another when no known cases were present. Two of three viral sequences derived from air samples were identical to measles outbreak patients. The source of one diverging sequence could not be identified and may represent a case not identified by traditional surveillance methods. Air sampling may supplement measles investigation, surveillance and response.
]]></description>
<dc:creator><![CDATA[ Barbian, H. J., Funk, M., Black, S. R., Hayden, M. K., Zelencik, S., Borah, B. F., Zhang, D., Bartlett, A. H., Kociolek, L. K., Rosenthal, A., Farhat, N., McSorley, V. E., Kittner, A. ]]></dc:creator>
<dc:date>2026-09-27</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26363929</dc:identifier>
<dc:title><![CDATA[Detecting measles virus in hospital air during a local outbreak]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-27</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.24.26363964v1?rss=1">
<title>
<![CDATA[
Nasopharyngeal aspirates and stool sample collection for molecular tuberculosis testing in children with severe pneumonia - a mixed methods study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.24.26363964v1?rss=1
</link>
<description><![CDATA[
BackgroundChild-friendly sample collection methods are needed to improve microbiological tuberculosis diagnosis in children. We assessed the feasibility, diagnostic yield, safety, tolerability, and acceptability of nasopharyngeal aspirates (NPA) and stool sample collection for XpertMTB/RIF Ultra (Ultra) testing in children <5 years with severe pneumonia in six high tuberculosis incidence countries.

MethodsWe conducted a cross-sectional mixed-methods study (10/2020-03/2021) nested within the TB-Speed Pneumonia trial (NCT03831906) in 15 tertiary hospitals. Uptake and diagnostic yield of NPA and stool, sampled by trained nurses, were computed. Nurses documented NPA feasibility and related adverse events. NPA tolerability was assessed through discomfort/distress/pain scales completed by nurses, parents/caregivers, and children >3 years. Individual interviews investigated nurses and parents/caregivers perceptions and experiences of both procedures.

ResultsOf 542 children enrolled, 541 (99.8%) and 423 (75.5%) had NPA and stool samples successfully collected, respectively; 8 (1.5%) had positive Ultra on any sample, 8 (1.5%) on NPA, and 3 (0.6%) on stool samples. Nurses reported that NPA was difficult to collect in 27 (5.0%) children. 130 (24%) children had bloodstained NPA samples and <5% experienced transient heart rate deceleration, digestive or respiratory distress during NPA. Median nurse-assessed tolerability scores were 1/10 [0,3] before and 5/10 [2,6] during NPA. Although most respondents perceived NPA as painful, all appreciated that NPA aimed to improve child health. Nurses reported that NPA and stool collection was quicker, less invasive than gastric aspiration. Parents/caregivers trusted nurses skills and valued the novelty of NPA. All respondents easily engaged in stool collection, but were frustrated to depend on children passing stool. Nurses underlined that continuous staff training and mentoring would sustain feasibility and self-efficacy in obtaining adequate samples.

ConclusionsNPA and stool are viable specimen collection options for microbiological diagnosis of tuberculosis in young children <5 years with severe pneumonia in high tuberculosis incidence countries.
]]></description>
<dc:creator><![CDATA[ Bhatta, B., Bunnet, D., Coleman, M., Massom, D. M., Djaha, J., Banga, M.-F. L., Kaing, S., Voss de Lima, Y., Mbalazi, K., Komena, E., Kwedi-Nolna, S., Cumbe, S., Natukunda, N., Shankalala, P., Nanfuka, M., Roucher, C., Lounnas, M., Huyen Ton Nu Nguyet, M., Vessiere, A., Maillard, A.-L., Ngu, E., Joshi, B., Borand, L., Moh, R., Khosa, C., Chabala, C., Mwanga-Amumpere, J., Taguebue, J.-V., Wobudeya, E., Bonnet, M., Marcy, O., Orne-Gliemann, J. ]]></dc:creator>
<dc:date>2026-09-27</dc:date>
<dc:identifier>doi:10.64898/2026.09.24.26363964</dc:identifier>
<dc:title><![CDATA[Nasopharyngeal aspirates and stool sample collection for molecular tuberculosis testing in children with severe pneumonia - a mixed methods study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-27</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.24.26363927v1?rss=1">
<title>
<![CDATA[
Falling short: Inadequate target attainment in guideline-based therapy of nontuberculous mycobacterial disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.24.26363927v1?rss=1
</link>
<description><![CDATA[
Nontuberculous mycobacterial (NTM) infections are a scourge that affect growing patient populations due to the rise of risk factors associated with these opportunistic pathogens. Cure rates are unacceptably low despite intensive multidrug and multi-year therapy. The issue of poor drug exposure relative to inferior potency of repurposed antibiotics against NTM pathogens is broadly recognized as a major factor underlying dismal success rates. Yet, a quantitative and systematic evaluation of probabilities of pharmacokinetic-pharmacodynamic (PK-PD) target attainment (PTA) is lacking. Here, we leveraged published population PK models and minimum inhibitory concentration distributions across large patient populations to generate PTAs for standard of care antibiotics used in the treatment of NTM infections. PTAs of tuberculosis drugs were included in our analysis as a baseline since tuberculosis cure rates are excellent compared to NTM diseases. We found that PK-PD target attainment for NTM was low overall and that PTAs were generally consistent with reported clinical outcomes. Specifically, drugs for which genetic resistance is associated with worse outcome showed favorable PTAs, consistent with their contribution to cure. These include macrolides for M. abscessus and the M. avium complex (MAC), and rifampicin for M. kansasii. Bedaquiline emerged as a promising option against M. abscessus and MAC, and clofazimine against the latter, consistent with recent clinical reports. Omadacycline PTAs predict improved efficacy compared to tigecycline for patients with M. abscessus and suggest clinical utility for MAC. As is common practice for antibacterials, PTA considerations could inform NTM treatment guidelines and help select drug combinations in future trials.
]]></description>
<dc:creator><![CDATA[ Shoaf, T. J., Dierckman, T., Strawhacker, N., Surani, M. d. L. M., Nair, M., Bawab, E., Escalante, P., Dick, T., Dartois, V. A., Pienaar, E. ]]></dc:creator>
<dc:date>2026-09-27</dc:date>
<dc:identifier>doi:10.64898/2026.09.24.26363927</dc:identifier>
<dc:title><![CDATA[Falling short: Inadequate target attainment in guideline-based therapy of nontuberculous mycobacterial disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-27</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.21.26363521v1?rss=1">
<title>
<![CDATA[
A within-host-informed event-time framework linking epidemiological delay distributions 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.21.26363521v1?rss=1
</link>
<description><![CDATA[
Understanding when and how pathogens spread from person to person is fundamental to characterizing transmission, interpreting surveillance data, and designing effective control measures. Yet key epidemiological delays--including the latent period, incubation period, generation interval, and serial interval--are difficult to estimate because key events such as infection, infectiousness, symptom onset, and transmission are rarely observed directly. Current approaches typically estimate these delays using flexible statistical distributions rather than explicitly linking them through the underlying processes that generate them, making it difficult to interpret the underlying biology and to ensure consistency across related delay estimates. Here, we develop a stochastic event-time framework built around a dynamic within-host pathogen-growth model that treats epidemiological delays as coupled outcomes of a shared biological process. By representing these key events as linked stochastic events, the framework produces internally consistent delay distributions while inferring parameters with mechanistic interpretations conditional on the assumed within-host model that govern pathogen growth, clearance, infectiousness, and symptom onset. The framework also accommodates censored and partially observed infection and symptom-onset times through a unified observation model. Across simulation studies, the framework accurately recovered generation-interval characteristics across sample sizes and disease time scales. In applications to SARS-CoV-2 and mpox transmission-pair data, the framework showed improved predictive fit relative to conventional lognormal delay models in several analyses, although the magnitude of improvement varied across datasets and observation models; it estimated shorter generation intervals for Omicron than Delta and revealed alternative within-host parameters compatible with the mpox transmission data. This mechanistic framework provides a biologically interpretable alternative to independently fitted delay distributions, yields internally consistent estimates of epidemiological delays, and establishes a foundation for integrating biological and epidemiological data to better understand, predict, and control pathogen transmission.

Author summaryFor many infections that spread directly from person to person, the timing of infection, infectiousness, symptom onset, and passing the infection to someone else is central to understanding how disease spreads. These delays are often estimated separately using statistical distributions, even though they are biologically connected. For example, the amount of pathogen in the body can influence when someone becomes infectious, when symptoms appear, and when transmission is most likely. We developed a modeling framework that links these timings through a shared pathogen growth process. In the model, becoming infectious, developing symptoms, and transmitting infection occur as chance events whose rates change with pathogen load. We tested the framework using simulations and data from recent SARS-CoV-2 and mpox epidemics, showing that it outperformed conventional statistical approaches and can incorporate pathogenload data into delay estimation, while providing new estimates of the generation intervals of recent COVID-19 variants and mpox. More broadly, the framework provides a way to combine epidemiological data with biological information, helping researchers understand how changes in within-host (WH) pathogen dynamics influence transmission and improving our ability to predict and control infectious disease outbreaks.
]]></description>
<dc:creator><![CDATA[ Jamieson, N., Park, S. W., Ainslie, K., Xu, J., Funk, S., Ward, T., Overton, C. E., Meyers, L. A., Abbott, S. ]]></dc:creator>
<dc:date>2026-09-26</dc:date>
<dc:identifier>doi:10.64898/2026.09.21.26363521</dc:identifier>
<dc:title><![CDATA[A within-host-informed event-time framework linking epidemiological delay distributions]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.22.26363724v1?rss=1">
<title>
<![CDATA[
Development and validation of a laboratory-developed test on Panther Fusion(R) system for detection of macrolide resistance in Bordetella pertussis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.22.26363724v1?rss=1
</link>
<description><![CDATA[
Macrolides remain the first-line antimicrobial treatment for pertussis, primarily caused by Bordetella pertussis. Emergence of macrolide-resistant B. pertussis in Australia and globally presents a growing concern for clinical management. As molecular diagnosis predominates for pertussis, limited numbers of cultures are available for antimicrobial susceptibility testing. The A2037G mutation in the 23S rRNA gene is most commonly associated with macrolide resistance in B. pertussis, yet no commercial molecular assay is available for its detection. In this study, we adapted and validated a previously published real-time PCR assay as a laboratory developed test (LDT) on the Panther Fusion(R) system using Open Access-functionality to detect the macrolide resistance-associated mutation in B. pertussis from culture isolates and clinical specimens. Total turnaround time was [~]2.5 h for the first result and 2-3 min for subsequent results in the same batch, with an estimated cost of AUD 18 per sample, excluding labour. A total of 30 samples were included in the validation panel to assess assay performance. All isolates and clinical specimens in the validation panel produced results concordant with the expected mutation status, demonstrating 100% accuracy, sensitivity and specificity. The assay demonstrated a limit of detection of 1.5 x 103 CFU/mL (22 CFU/reaction). This Panther Fusion(R) LDT provides a rapid and fully automated approach for molecular detection of the targeted mutation associated with macrolide resistance in B. pertussis. Its integration into routine molecular workflows as a reflex test following identification of B. pertussis may facilitate timely identification of resistant infections.
]]></description>
<dc:creator><![CDATA[ Sadeesh Kumar, L., Sait, M., Howden, B. P., Sherry, N. L. ]]></dc:creator>
<dc:date>2026-09-25</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.26363724</dc:identifier>
<dc:title><![CDATA[Development and validation of a laboratory-developed test on Panther Fusion(R) system for detection of macrolide resistance in Bordetella pertussis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.24.26363858v1?rss=1">
<title>
<![CDATA[
Toward personalized and longitudinal antibiograms--a proof-of-concept for in vivo assessments of immunological-antibiotic-bacterial interactions 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.24.26363858v1?rss=1
</link>
<description><![CDATA[
IntroductionIn vivo, temporal, and personalized data on immunological-antibiotic interactions may provide richer, earlier information that improves infection treatment. To test this hypothesis, we applied a proof-of-concept approach to evaluate a non-reductionist methodology.

MethodsA non-reductionist, data-driven, pattern recognition-based combinatorial method that captures relationships was evaluated with blood leukocyte data collected from 401 individuals from Greece [n=331] and the US [n=70] who experienced sepsis, pneumonia, endocarditis, tuberculosis, syphilis, skin and soft tissue, intra-abdominal, or urinary tract infections associated with meningitis.

ResultsWhile ambiguity was observed when variables were measured in isolation by a reductionist alternative, ambiguity was prevented and hidden information was uncovered when complex dynamics were assessed by the non-reductionist method. The combinatorial approach grouped together observations that displayed similar immune profiles, distinguished those with different mortality risks, identified antibiotics that modulated specific leukocytes, differentiated two types of non-responsiveness (associated or not associated with antibiotics), and facilitated earlier and personalized evaluation of therapies. For instance, in tuberculosis, blood monocytes were modulated by isoniazid-related antimicrobials.

DiscussionAcross numerous syndromes, the non-reductionist method extracted more information from the same data than the reductionist alternative. If corroborated, non-reductionist methodologies may promote research and support personalized medicine.
]]></description>
<dc:creator><![CDATA[ Iandiorio, M. J., Ioannidis, A., Kempaiah, P., Fasina, F. O., Madaki, P. D., Fazio, J. C., Fasina, M. M., Rojas Gil, A. P., Chatzipanagiotou, S., Gerotziafas, G., Hoogesteijn, A. L., Fair, J. M., Rivas, A. L. ]]></dc:creator>
<dc:date>2026-09-25</dc:date>
<dc:identifier>doi:10.64898/2026.09.24.26363858</dc:identifier>
<dc:title><![CDATA[Toward personalized and longitudinal antibiograms--a proof-of-concept for in vivo assessments of immunological-antibiotic-bacterial interactions]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363816v1?rss=1">
<title>
<![CDATA[
Genetic Relationships of Third-Generation Cephem Resistant Escherichia coli in Humans, Dogs and Cattle using a Novel Clonotyping Assay 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363816v1?rss=1
</link>
<description><![CDATA[
Antimicrobial resistance is a global  One Health threat connecting antimicrobial use in human health, animal husbandry, and companion animal health with concern for persistence in environmental reservoirs. Complicating this threat is the gap that exists in our understanding of the intersection of antimicrobial resistance among humans and our companion and food production animals. This study applies a visual and statistical approach to further understand antimicrobial resistance characteristics and relatedness of Escherichia coli found in humans, dogs and cattle. The primary study collection included third-generation cephem resistant (3GCR) E. coli isolates recovered from human, dog, and cattle gastrointestinal specimens and secondarily human and dog isolates recovered from infection sources, primarily urinary tract infections. We previously reported on the transferable gene targets encoding for 3GCR in colonizing isolates and here further identified the familial-like clonal group of each resistant isolate using a novel clonotype diagnostic (septatyping). Together, this approach identified distinct genetic signatures among these 3GCR isolates, many of which are peculiar to their respective host species. We found that the overlap measured by the correlation in abundance of shared clonotypes of resistant E. coli among hosts revealed statistically greater similarity between dogs and humans than between cattle and humans. Yet, the reservoir of AMR genes was highest in cattle and secondarily dogs. While these findings demonstrate that clonotypes of 3GCR E. coli in humans, dogs and cattle display significant host specificity, transient colonization from a host enriched with resistant strains may still pose considerable risk of horizontal transfer of resistance genes between hosts living in proximity to each other.
]]></description>
<dc:creator><![CDATA[ Legenza, L., Jonaitis, E. M., Lee, J. D., Sokourenko, E. V., Tchesnokova, V., Hite, J. L., Gao, S., Olson, B. J., Fritsche, T. R. ]]></dc:creator>
<dc:date>2026-09-25</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363816</dc:identifier>
<dc:title><![CDATA[Genetic Relationships of Third-Generation Cephem Resistant Escherichia coli in Humans, Dogs and Cattle using a Novel Clonotyping Assay]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.22.26363691v1?rss=1">
<title>
<![CDATA[
National trends of unique-PCV20 / PCV21 serotypes, common PCV20-PCV21 and non-vaccine serotypes causing invasive pneumococcal disease in adults in Spain during the period 2009-2026 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.22.26363691v1?rss=1
</link>
<description><![CDATA[
ObjectivesTo evaluate the epidemiological evolution of unique pneumococcal serotypes covered by either PCV20 or PCV21, common serotypes by both vaccines and non-vaccine serotypes in adults.

MethodsWe characterized all national IPD clinical isolates from January 2009 to June 2026.

ResultsThe highest burden of IPD was caused by serotypes shared between PCV20 and PCV21 with serotypes 3 and 8 the most prevalent in adults of all ages. During the pre-pandemic period, IPD caused by unique-PCV20 serotypes declined probably due to herd protection by paediatric vaccination with PCVs. In contrast, unique-PCV21 serotypes increased in incidence accounting for more cases than unique-PCV20 serotypes. However, after the COVID-19 pandemic, a different pattern was observed with unique-PCV20 serotypes increasing in incidence due a marked rise in IPD caused by serotypes 4 and 14 that has progressively reduced the gap in disease coverage. In adults aged 18-64 years, the fraction of disease that could be prevented with PCV20/PCV21 changed from 5% in favour of PCV21 (years 2022/2023) to 15% in favour of PCV20 (year 2026) whereas in adults [&ge;]65 years the vaccine contribution declined from 20% in favour of PCV21 (year 2022) to 8% in 2026.

ConclusionsIPD trends in adults have changed after the COVID-19 pandemic, especially in recent years. Our study emphasizes the rapid re-emergence of infections caused by traditional PCV7 serotypes especially serotypes 4 and 14 and reinforce the idea that the use of broader PCVs must be accompanied by an increase in the uptake rates in adults of all ages.
]]></description>
<dc:creator><![CDATA[ Garcia-Gonzalez, E., Sempere, J., Llamosi, M., Perez-Garcia, C., Ubeda, A., Sanchez-Honrado, A., Agullo, L., Ardanuy, C., Perez-Fernandez, L., Ocampo-Sosa, A., Ramos-Sevillano, E., Brown, J. S., Domenech, M., Yuste, J. ]]></dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.26363691</dc:identifier>
<dc:title><![CDATA[National trends of unique-PCV20 / PCV21 serotypes, common PCV20-PCV21 and non-vaccine serotypes causing invasive pneumococcal disease in adults in Spain during the period 2009-2026]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363603v1?rss=1">
<title>
<![CDATA[
Mind the Gaps: Validating species presence under sparse genomic recovery in clinical metagenomics 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363603v1?rss=1
</link>
<description><![CDATA[
1Clinical metagenomic sequencing is increasingly used to detect pathogens directly from clinical samples, but sparse and uneven genome recovery caused by low microbial biomass and stochastic fragment loss makes species-level validation difficult. Under these conditions, the same observed coverage may arise either from genuine genome-wide representation or from reads confined to conserved loci shared among related taxa. Current heuristic thresholds based on read counts, breadth or related alignment summaries target the realised coverage rather than the generating process. We show that, under hidden fragment loss, coverage is the wrong inferential object for uniformly valid species-level inference. What remains informative is the spatial dispersion of surviving reads across genomic coordinates. This change of inferential object allows us to ask how much of the candidate genome must be represented in any source capable of reproducing the observed evidence. This yields the Metagenomic Alignment Validation Index (MAVI), a conservative lower bound on the fraction of the candidate genome required to explain the observed read dispersion. MAVI therefore provides an error-controlled, interpretable measure of genomic confidence: the minimum genomic content a competing source would need to share with the candidate to mimic the observed evidence. Evaluated across 643 long-read metagenomic samples, including 280 clinical samples, MAVI reproduced independently supported organism calls, resolved sparse low-coverage ambiguities and exposed workflow-level collapse of stochastic dispersion, without relying on heuristic coverage thresholds.
]]></description>
<dc:creator><![CDATA[ Behruznia, M., Silva-Toro, F., Marquez, D. A. ]]></dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363603</dc:identifier>
<dc:title><![CDATA[Mind the Gaps: Validating species presence under sparse genomic recovery in clinical metagenomics]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.22.26363646v1?rss=1">
<title>
<![CDATA[
Genitourinary Brucellosis in an Endemic Region: Clinical Spectrum, Diagnostic Pitfalls and Treatment Outcomes of a 13-Year Retrospective Cohort 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.22.26363646v1?rss=1
</link>
<description><![CDATA[
AimBrucellosis remains endemic throughout the Mediterranean basin, the Middle East and Central Asia. Genitourinary involvement is an uncommon but clinically consequential focal complication that closely mimics urological emergencies and may precipitate unnecessary surgery. Contemporary data describing its frequency, laboratory signature and treatment outcomes in endemic settings remain limited.

Material-MethodsWe retrospectively screened all adults ([&ge;]18 years) with confirmed brucellosis managed at a tertiary infectious diseases unit between January 2008 and December 2020. Genitourinary involvement was defined as epididymo-orchitis, orchitis, epididymitis and/or brucellar pyelonephritis. Clinical, laboratory, ultrasonographic, therapeutic and outcome variables were abstracted using a standardised form. Proportions are reported with Wilson score 95% confidence intervals (CI). Reporting followed the STROBE statement.

ResultGenitourinary involvement was identified in 18 of 125 patients with brucellosis (14.4%; 95% CI 9.3-21.6); 16 (88.9%) were men and the mean age was 35.2 years (range 22-62). Scrotal disease dominated the male presentation: epididymo-orchitis in 10 of 16 men (62.5%; 95% CI 38.6-81.5), orchitis in 4 (25.0%) and epididymitis in 2 (12.5%). Both women presented with pyelonephritis, one of whom developed a tubo-ovarian abscess requiring drainage. Constitutional features were near-universal (fatigue 100%, night sweats 88.9%, fever 77.8%). Leukocyte counts remained within the reference interval in every patient (mean 5,680/mm3), whereas erythrocyte sedimentation rate (mean 32 mm/h) and C-reactive protein (mean 24.2 mg/L) were only mildly to moderately raised. The Coombs anti-Brucella test was positive in 18 of 18 patients (100%) and the standard agglutination test in 17 of 18 (94.4%), whereas blood culture yielded Brucella melitensis in only 1 of 18 (5.6%). Concomitant extragenitourinary focal disease was present in 8 patients. All patients received doxycycline plus rifampicin; none required modification of the regimen or orchiectomy, and no treatment failure occurred (0 of 18; 95% CI 0-17.6). Median follow-up was 12 weeks (range 6-52) and no relapse was documented within this interval.

ConclusionsIn endemic regions, genitourinary brucellosis should be suspected in any patient with acute scrotal or flank symptoms accompanied by constitutional complaints, even when the leukocyte count is normal and acute-phase reactants are only marginally elevated. Coombs anti-Brucella serology rather than blood culture is the diagnostic cornerstone, and prompt doxycycline-rifampicin therapy averts surgical intervention.
]]></description>
<dc:creator><![CDATA[ Savas, L., Pekok, A. U., Pekok, B. S., Eser, Z. S. ]]></dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.26363646</dc:identifier>
<dc:title><![CDATA[Genitourinary Brucellosis in an Endemic Region: Clinical Spectrum, Diagnostic Pitfalls and Treatment Outcomes of a 13-Year Retrospective Cohort]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.22.26363659v1?rss=1">
<title>
<![CDATA[
Whole genome sequencing reveals a decade of human adenovirus B114 circulation in England 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.22.26363659v1?rss=1
</link>
<description><![CDATA[
BackgroundHuman Mastadenovirus B (HAdV-B) causes ocular and respiratory infections and is capable of causing outbreaks in healthcare settings. HAdV-B114, a recombinant genotype only formally recognised in 2023, has been reported predominantly from Germany, the USA, China and Japan; genomic data from UK clinical settings remain limited. This study analysed 68 HAdV-B whole genomes from ocular and respiratory-associated samples collected at a Nottingham hospital across the pre- and post-COVID-19 restriction periods (2017-2023).

MethodsClinical samples typed positive for HAdV-B by partial hexon Sanger sequencing were selected for whole-genome sequencing using a novel overlapping PCR amplicon strategy, sequenced on the Oxford Nanopore Technologies PromethION platform. Phylogenetic and pairwise difference analyses were used to characterise genotype composition and genomic relatedness. SimPlot and amino-acid comparison characterised divergence between sub-lineages.

ResultsWhole-genome phylogenetics confirmed that two species B genotypes were detected in Nottingham University Hospitals between 2017-23: HAdV-B114 (n=56) and HAdV-B7 (n=12). HAdV-B114 was detected before and after COVID-19 restrictions, with an increase in 2022-2023, consistent with post-restriction expansion of a pre-existing lineage. Pairwise difference analysis identified 24 genomically identical B114 sequences; associated metadata argued against a single nosocomial transmission chain interpretation, with the pattern more consistent with repeated detection of a widely circulating community strain, with the possibility of localised onward transmission. Within the B114 clade, multiple monophyletic groups were identified by whole-genome phylogenetics.

ConclusionsThis study adds whole-genome resolution to the existing UK HAdV-B114 data, demonstrates the utility of WGS for clinical adenovirus surveillance and shows the benefits of combining epidemiological data with genomic analysis.
]]></description>
<dc:creator><![CDATA[ McClure, P. J., Muntean, M., Cifelli, E., Abiodun, O. J., Lister, M., Lambisia, A., Quick, J., Astbury, S., Houldcroft, C. J. ]]></dc:creator>
<dc:date>2026-09-23</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.26363659</dc:identifier>
<dc:title><![CDATA[Whole genome sequencing reveals a decade of human adenovirus B114 circulation in England]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.22.26363680v1?rss=1">
<title>
<![CDATA[
Respiratory Syncytial Virus infections in immunosuppressed adults <65 years old: a comparative analysis with Influenza and SARS-CoV2 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.22.26363680v1?rss=1
</link>
<description><![CDATA[
ObjectivesRespiratory Syncytial Virus (RSV) vaccine policies have varied globally since their approval in 2023. In the UK, policy has adapted in line with National evidence generation such that from Autumn 2026 at-risk persons [&ge;]65 years old will become eligible for vaccination. Immunosuppressed persons <65 years will still not be offered protection. The objective of this study is to investigate the relative burden of RSV infection by age and immunosuppressed status (IC).

DesignRetrospective observational cohort study using routine healthcare data from North West London Integrated Care System.

ParticipantsPatients with a confirmed diagnosis of a respiratory viral infection (RSV, Influenza A and B, SARS-CoV2) between October 2021 and July 2025.

Main outcomes measuresPrevalence and severity of RSV infection in immunosuppressed persons <65 years old, and to provide a comparative analysis with Influenza and SARS-CoV2 in a sub-cohort tested using a 4-in-1 combined rapid PCR test.

ResultsDuring the study period, 1226 patients were diagnosed with RSV of whom 596 (48.6%) were <65 years old. In 1091 patients with clinical data, 341 (31.3%) were IC. Fifty (9.9%) patients <65 years old had severe infection (ICU admission or death within 28 days of diagnosis), of whom 14 (28.0%) were IC. Proportionally, 16.7% of all RSV-associated deaths and 55.1% of all ICU RSV-admissions occurred in adult patients <65 years old.

RSV accounted for 665 (10.1%) infections confirmed by 4-in-1 viral PCR testing. Eight-nine (13.4%), 172 (9.3%) and 448 (12.0%) patients with RSV, Influenza A and SARS-COV2 experienced severe infection, of whom 32 (36.0%), 82 (47.7%) and 156 (34.8%) were <65 years old respectively. Eight (25.0%), 20 (24.4%) and 52 (33.3%) of patients <65 years old with severe infection were IC. On adjusted analysis, having an immunosuppressive condition increased the odds of a severe SARS-CoV2 infection, OR (95% CI) 1.36 (1.08-1.71) but not a severe RSV or Influenza infection.

ConclusionsSevere RSV infections occur in persons <65 years old, with a significant proportion of patients having an immunosuppressive condition. Urgent research is needed to investigate the potential benefit of extending the current UK RSV vaccine policy to protect younger immunosuppressed adults.
]]></description>
<dc:creator><![CDATA[ Danysz, M., Barnes, E., Lim, S. H., Richter, A. H., Stuart, B., Willicombe, M. ]]></dc:creator>
<dc:date>2026-09-23</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.26363680</dc:identifier>
<dc:title><![CDATA[Respiratory Syncytial Virus infections in immunosuppressed adults <65 years old: a comparative analysis with Influenza and SARS-CoV2]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-23</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
